-
公开(公告)号:WO2009026422A2
公开(公告)日:2009-02-26
申请号:PCT/US2008073830
申请日:2008-08-21
Applicant: ABBOTT LAB , BITNER R SCOTT , BROWMAN KAITLIN E , BRUNE MICHAEL E , CHEN YIXIAN , DINGES JURGEN , DRESCHER KARLA , JACOBSON PEER , JAE HWAN-SOO , KURUKULASURIYA RAVI , LINK JAMES T , MADAR DAVID J , PATEL JYOTI R , PLIUSHCHEV MARINA A , ROHDE JEFFREY J , RUETER LYNNE E , SHUAI QI , SORENSEN BRYAN K , WANG JIAHONG , WICKE KARSTEN M , WINN MARTIN , WODKA DARIUSZ , YEH VINCE , YONG HONG
Inventor: BITNER R SCOTT , BROWMAN KAITLIN E , BRUNE MICHAEL E , CHEN YIXIAN , DINGES JURGEN , DRESCHER KARLA , JACOBSON PEER , JAE HWAN-SOO , KURUKULASURIYA RAVI , LINK JAMES T , MADAR DAVID J , PATEL JYOTI R , PLIUSHCHEV MARINA A , ROHDE JEFFREY J , RUETER LYNNE E , SHUAI QI , SORENSEN BRYAN K , WANG JIAHONG , WICKE KARSTEN M , WINN MARTIN , WODKA DARIUSZ , YEH VINCE , YONG HONG
IPC: A61K31/495 , A61K31/44
CPC classification number: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-ß-hydroxysteroid dehydrogenase Type 1 enzyme activity.
Abstract translation: 用于治疗患有与糖尿病相关的中枢神经系统与衰老和神经变性有关的障碍和缺陷的患者的方法,其包括一般的注意力缺陷障碍,注意力缺陷多动障碍(ADHD),阿尔茨海默病(AD),轻度认知障碍 老年痴呆症,艾滋病痴呆症,神经变性,抑郁症和精神分裂症的方法,包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
公开(公告)号:CA2568241C
公开(公告)日:2015-01-20
申请号:CA2568241
申请日:2005-04-29
Applicant: ABBOTT LAB
Inventor: LINK JAMES T , PLIUSHCHEV MARINA A , ROHDE JEFFREY J , WODKA DARIUSZ , PATEL JYOTI R , SHUAI QI
IPC: C07D213/06 , A61K31/44 , A61K31/445 , C07C237/04 , C07C237/24 , C07D207/02 , C07D209/08 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, for example the compound of Formula I. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action. (see Formula I)
-
公开(公告)号:NZ587997A
公开(公告)日:2012-04-27
申请号:NZ58799705
申请日:2005-04-29
Applicant: ABBOTT LAB
Inventor: LINK JAMES T , PLIUSHCHEV MARINA A , ROHDE JEFFREY J , WODKA DARIUSZ , PATEL JYOTI R , SHUAI QI
IPC: C07D213/24 , C07C237/04 , C07C237/24 , C07D207/02 , C07D209/08 , C07D213/06 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: Disclosed is a substituted adamantine compound selected from the group consisting of: N2- [2-(4-chlorophenyl)ethyl] -N1-[(E)-5-hydroxy-2-adamantyl]alaninamide; N2-[2-(3,4-dichlorophenyl)ethyl] -N1-[(E)-5-hydroxy-2-adamantyl] -N2-methylalaninamide; N2-[2-(4-chlorophenyl)-1-methylethyl] -N1-[(E)-5-hydroxy-2-adamantyl]-N2-methylalaninamide; N-[(E)-5-hydroxy-2-adamantyl]-1-{ [4-(trifluoromethyl)benzyl]amino} cyclopropanecarboxamide; 2-[(cis)-2,6-dimethylmorpholin-4-yl] -N-[(E)-5-hydroxy-2-adamantyl]propanamide; 2-azepan-1-yl-N-[(E)-5-hydroxy-2-adamantyl]propanamide; N-[(E)-5-hydroxy-2-adamantyl]-2-(6,7,9,10-tetrahydro-8H-[1,3]dioxolo[4,5-g] [3]benzazepin-8-yl)propanamide; 2-(1,3-dihydro-2H-isoindol-2-yl)-N- [(E)-5-hydroxy-2-adamantyl]propanamide; 2- [3-(4-chlorophenoxy)azetidin- 1-yl]-N-[(E)-5-hydroxy-2-adamantyl]propanamide; 2-(5-chloro-2,3-dihydro-1H-indol- 1-yl)-N-[(E)-5 -hydroxy-2-adamantyl]propanamide; N-[(E)-5-hydroxy-2-adamantyl] -2-(3-phenylazetidin-1-yl)propanamide; 2-[3-(3-fluorophenoxy)pyrrolidin-1-yl]-N-[(E)-5-hydroxy-2-adamantyl]propanamide; N-[(E)-5-hydroxy-2-adamantyl]-2-methyl-2- [2-(trifluoromethyl)pyrrolidin-1-yl]propanamide; N-[(Z)-5-hydroxy-2-adamantyl]-2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} acetamide; N-[(E)-5-hydroxy-2-adamantyl] -2-{ 4-[5 -(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} acetamide; (2S)-N-[(E)-5-hydroxy-2-adamantyl] -2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide; (2R)-N- [(E)-5 -hydroxy-2-adamantyl] -2- { 4- [5 -(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide; N-[(E)-5-fluoro-2-adamantyl] -2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} acetamide; N-[(Z)-5-fluoro-2-adamantyl] -2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} acetamide; N-[(E)-5-hydroxy-2-adamantyl] -2-[4-(5-methylpyridin-2-yl)piperazin-1-yl]propanamide; N-[(E)-5-hydroxy-2-adamantyl] -2-methyl-2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide; N-[(E)-5-hydroxy-2-adamantyl]-2-(4-pyridin-2-ylpiperazin-1-yl)propanamide; 2- [4-(4-fluorophenyl)piperazin-1-yl]-N-[(E)-5-hydroxy-2-adamantyl]propanamide; N-[(E)-5-hydroxy-2-adamantyl]-2-[4-(4-methoxyphenyl)piperazin-1-yl]propanamide; 2-[4-(5-cyanopyridin-2-yl)piperazin-1-yl]-N-[(E)-5-hydroxy-2-adamantyl]propanamide; 2-[4-(2-furoyl)piperazin-1-yl]-N-[(1R,3S)-5-hydroxy-2-adamantyl]propanamide; N-[(E)-5-hydroxy-2-adamantyl] -2-{ 4-[4-(trifluoromethyl)phenyl]piperazin-1-yl} propanamide; (2S)-N-[(E)-5-hydroxy-2-adamantyl] -2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide; (2R)-N-[(E)-5-hydroxy-2-adamantyl] -2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide; 2-[4-(6-chloropyridin-3 yl)piperazin-1-yl]-N-[(E)-5-hydroxy-2-adamantyl]propanamide; 2-(4-benzylpiperidin-1-yl)-N-[(E)-5-hydroxy-2-adamantyl]propanamide; 2-[4-(2-fluorophenoxy)piperidin-1-yl] -N-[(E)-5-hydroxy-2-adamantyl]propanamide; 2-[3-(2-fluorophenoxy)piperidin-1-yl] -N-[(E)-5-hydroxy-2- adamantyl]propanamide; N- [(E)-5 -cyano-2-adamantyl] -2-methyl-2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide; and N-[(E)-5-(cyanomethyl)-2-adamantyl]-2-methyl-2-{ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide. Also disclosed is a pharmaceutical composistin comprisining a compound and the use of the compound for the manufacture ofa medicament for treating Cushing's syndrome, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, hypertension, atherosclerosis, glaucoma, and osteoporosis. The compounds are useful as 11-beta-HSD inhibitors.
-
公开(公告)号:MXPA06013980A
公开(公告)日:2007-03-15
申请号:MXPA06013980
申请日:2005-04-29
Applicant: ABBOTT LAB
Inventor: LINK JAMES T , PLIUSHCHEV MARINA A , ROHDE JEFFREY J , WODKA DARIUSZ , PATEL JYOTI R , SHUAI QI
IPC: C07D213/06 , A61K31/00 , C07C237/04 , C07C237/24 , C07D207/02 , C07D209/08 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: La presente invencion se refiere a compuestos que son inhibidores de la enzima Tipo I de 11-beta-hidroxiesteroide deshidrogenasa. La presente invencion se refiere ademas al uso de inhibidores de enzima Tipo I de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de la diabetes tipo 2 no dependiente de la insulina, resistencia a la insulina, obesidad, enfermedades de lipidos, sindrome metabolico y otras enfermedades y padecimientos que son transmitidos por la accion excesiva de glucocorticoides.
-
公开(公告)号:AU2005241073A1
公开(公告)日:2005-11-17
申请号:AU2005241073
申请日:2005-04-29
Applicant: ABBOTT LAB
Inventor: ROHDE JEFFREY J , PATEL JYOTI R , PLIUSHCHEV MARINA A , WODKA DARIUSZ , LINK JAMES T , SHUAI QI
IPC: C07D207/02 , C07C237/04 , C07C237/24 , C07D209/08 , C07D213/06 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
公开(公告)号:UY33726A
公开(公告)日:2012-06-29
申请号:UY33726
申请日:2011-11-11
Applicant: ABBOTT LAB
Inventor: WOLLER KEVIN R , HELMUT MACK , CURTIN MICHAEL L , SORENSEN BRYAN K , HEYMAN HOWARD R , CLARK RICK F , SHAH OMAR J , MICHAEL MICHAELIDES , CHRIS TSE , ANIL VASUDEVAN , HANSEN TODD M , RAMZI SWEIS , PLIUSHCHEV MARINA A
IPC: A61K31/341 , A61K31/357 , A61K31/381 , A61K31/4015 , A61K31/4025 , A61K31/4035 , A61K31/4155 , A61K31/416 , A61K31/427 , A61K31/4355 , A61K31/438 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D205/12 , C07D209/44 , C07D223/10 , C07D231/02 , C07D231/56 , C07D237/02 , C07D239/02 , C07D241/02 , C07D265/32 , C07D277/02 , C07D295/033 , C07D307/02 , C07D317/10 , C07D319/16 , C07D333/48 , C07D401/14 , C07D403/02 , C07D403/14 , C07D405/02 , C07D471/04 , C07D471/10 , C07D491/048 , C07D491/113
Abstract: Compuestos que inhiben la actividad de la NAMPT, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la NAMPT. Compuestos que inhiben la actividad de la ROCK, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la ROCK.
-
公开(公告)号:NZ551508A
公开(公告)日:2010-10-29
申请号:NZ55150805
申请日:2005-04-29
Applicant: ABBOTT LAB
Inventor: LINK JAMES T , PLIUSHCHEV MARINA A , ROHDE JEFFREY J , WODKA DARIUSZ , PATEL JYOTI R , SHUAI QI
IPC: C07D207/02 , C07C237/04 , C07C237/24 , C07D209/08 , C07D213/06 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: Disclosed is a compound according to formula (I) wherein A1 is alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, arylalkyl, aryloxyalkyl, carboxyalkyl, carboxycycloalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, -NR7-[C(R8R9)]n-C(O)-R10, -O-[C(R11R12)]p-C(O)-R13, -N(R15R16), -CO2R17, -C(O)-N(R18R19), -CR20R21)-OR22, or -C(R23R24)-N(R25R26); and wherein the rest of the substituents are disclosed within the specification. Also disclosed is the use of a compound of formula (I) in the manufacture of a medicament for treating a disorder associated with the inhibition of 11-beta-hydroxysteroiddehydrogenase type 1 enzyme selected from Cushing's syndrome, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, hypertension, atherosclerosis, glaucoma, and osteoporosis.
-
公开(公告)号:CA2568241A1
公开(公告)日:2005-11-17
申请号:CA2568241
申请日:2005-04-29
Applicant: ABBOTT LAB
Inventor: ROHDE JEFFREY J , WODKA DARIUSZ , SHUAI QI , PATEL JYOTI R , LINK JAMES T , PLIUSHCHEV MARINA A
IPC: C07D213/06 , A61K31/44 , A61K31/445 , C07C237/04 , C07C237/24 , C07D207/02 , C07D209/08 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
公开(公告)号:ECSP13012993A
公开(公告)日:2014-01-31
申请号:ECSP13012993
申请日:2013-06-13
Applicant: ABBOTT LAB
Inventor: WOLLER KEVIN ROGER , CURTIN L MICHAEL , MACK HELMUT , MICHAELIDES MICHAEL R , HANSEN TODD M , VASUDEVAN ANIL , SORENSEN BRYAN K , HEYMAN HOWARD R , CLARK RICHARD F , SHAH OMAR J , TSE CHRIS , SWEIS RAMZI , PLIUSHCHEV MARINA A
IPC: C07D209/44 , A61K31/4035 , A61K31/407 , A61P9/10 , A61P35/00 , C07D403/12 , C07D407/12 , C07D407/14 , C07D413/12 , C07D471/04
Abstract: Compuestos que inhiben la actividad de la NAMPT, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la NAMPT. Compuestos que inhiben la actividad de la ROCK, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la ROCK.
-
公开(公告)号:AR083855A1
公开(公告)日:2013-03-27
申请号:ARP110104229
申请日:2011-11-11
Applicant: ABBOTT LAB
Inventor: CURTIN MICHAEL L , SORENSEN BRYAN K , HEYMAN HOWARD R , CLARK RICK F , WOLLER KEVIN R , SHAH OMAR J , MICHAELIDES MICHAEL , TSE CHRIS , VASUDEVAN ANIL , MACK HELMUT , HANSEN TODD M , SWEIS RAMZI , PLIUSHCHEV MARINA A
IPC: C07D209/44 , A61K31/4035 , A61K31/407 , A61P35/00 , C07D401/14 , C07D403/12 , C07D403/14 , C07D407/12 , C07D407/14 , C07D413/12 , C07D413/14 , C07D471/04
Abstract: Compuestos que inhiben la actividad de la NAMPT, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la NAMPT. Compuestos que inhiben la actividad de la ROCK, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la ROCK.Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), y sus sales farmacéuticamente aceptables, donde X1, X2, y X3 son CH; o X1 y X3 son CH; y X2 es N; o X1 y X3 son CH; y X2 es CR1; o X2 y X3 son CH; y X1 es CR1; o X1 es CH; y X2 y X3 son CR1; o X2 es CH; y X1 y X3 son N; o X2 y X3 son CH; y X1 es N; o X1 es CH; X2 es N; y X3 es CR1; o X1 es CR1; X2 es N; y X3 es CH; o X1 es N; X2 es CR1; y X3 es CH; o X1 es N; X2 es CR1; y X3 es N; R1 es R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, o C(O)NH2; R2 es alquilo, alquenilo, alquinilo, fenilo, heterociclilo, cicloalquilo, o cicloalquenilo; donde cada R2 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, CO(O)R4, OC(O)R4, OC(O)OR4, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br o I; donde cada R2 fenilo se sustituye opcionalmente en la posición para con un sustituyente seleccionado en forma independiente entre R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br o I; donde cada R2 fenilo está además opcionalmente sustituido con un F; donde cada R2 heterociclilo, cicloalquilo, y cicloalquenilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br o I; R3, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, o heterociclilo; donde cada R3 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br o I; R4, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, cicloalquilo, o heterociclilo; donde cada R4 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br o I; donde cada R4 arilo y heterociclilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R8 , OR8 , SR8, S(O)R8, SO2R8 , C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br o I; R5, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; donde cada R5 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br o I; R6, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; donde cada R6 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br o I; R7, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; donde cada R7 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R11, OR11, SR11, S(O)R11, SO2R11, NHR11, N(R11)2, C(O)R11, C(O)NH2, C(O)NHR11, C(O)N(R11)2, NHC(O)R11, NR11C(O)R11, NHSO2R11, NHC(O)OR11, SO2NH2, SO2NHR11, SO2N(R11)2, NHC(O)NH2, NHC(O)NHR11, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br o I; R8 en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; donde cada R8 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R12, OR12, SR12, S(O)R12, SO2R12, NHR12, N(R12)2, C(O)R12, C(O)NH2, C(O)NHR12, C(O)N(R12)2, NHC(O)R12, NR12C(O)R12 NHSO2R12, NHC(O)OR12, SO2NH2, SO2NHR12, SO2N(R12)2, NHC(O)NH2, NHC(O)NHR12, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br o I; R9, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; donde cada R9 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre alcoxi, OH, cicloalquilo, arilo, o heterociclilo; R10, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; R11, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; R12, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, o cicloalquenilo; donde cada R12 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno o más alcoxi; donde las unidades cíclicas representadas por R3, R5, R6, R7, R8, R9, R10, R11, y R12 se sustituyen opcionalmente con uno, dos, tres, cuatro, cinco o seis sustituyentes seleccionados en forma independiente entre R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br o I; R13, en cada caso, es un sustituyente seleccionado en forma independiente entre alquilo, alquenilo, alquinilo, arilo, tetrahidrofuranilo, piridazinilo, pirazinilo, pirimidinilo, piridinilo, tieno[3,2-c]piridinilo, furo[3,2-c]piridinilo, pirrolidin-2-onilo, 1,1-dioxidotetrahidrotien-3-ilo, 1,1-dioxidotetrahidro-2H-tiopiran-3-ilo, dioxanilo, tetrahidropiranilo, piperidinilo, pirimidinilo, oxazolilo, pirazolilo, tiazolilo, pirrolidinilo, pirrolilo, tienilo, furanilo, morfolinilo, isooxazolilo, cicloalquilo, o cicloalquenilo; donde cada R13 alquilo, alquenilo, y alquinilo se sustituye opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados en forma independiente entre R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br o I; donde cada R13 a
-
-
-
-
-
-
-
-
-